
1. lancet hiv. 2018 jun;5(6):e317-e328. doi: 10.1016/s2352-3018(18)30039-0.

barriers strategies achieve cure hiv.

pitman mc(1), lau jsy(2), mcmahon jh(3), lewin sr(4).

author information: 
(1)the peter doherty institute infection immunity, university of
melbourne, royal melbourne hospital, melbourne, vic, australia.
(2)department infectious diseases, monash university, alfred hospital,
melbourne, vic, australia.
(3)department infectious diseases, monash university, alfred hospital,
melbourne, vic, australia; department infectious diseases, monash medical
centre, clayton, vic, australia.
(4)the peter doherty institute infection immunity, university of
melbourne, royal melbourne hospital, melbourne, vic, australia; department of
infectious diseases, monash university, alfred hospital, melbourne, vic,
australia. electronic address: sharon.lewin@unimelb.edu.au.

9 years since report cure hiv c-c chemokine receptor type 5
δ32 stem cell transplantation, case hiv cure reported,
despite much research. however, substantial progress made in
understanding biology latent hiv reservoir, measuring the
amount virus persists antiretroviral therapy (art) with
increasingly sophisticated approaches. knowledge translated 
long pipeline clinical trials seeking reduce viral persistence in
participants suppressive treatment ultimately allow safe cessation of
art. review, discuss main barriers preventing development of
an hiv cure, methods used measure hiv persistence individuals art,
clinical strategies aim cure hiv, future directions studies in
the field hiv cure research.

copyright © 2018 elsevier ltd. rights reserved.

doi: 10.1016/s2352-3018(18)30039-0 
pmcid: pmc6559798
pmid: 29893245  [indexed medline]

